These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26563809)

  • 1. Effect of low-dose mineralocorticoid receptor antagonists on metabolic profile and endothelial dysfunction in metabolic syndrome.
    Kanchan V; Pawan K; Sudhir V; Harpreet Singh K
    Diabetes Metab; 2016 Feb; 42(1):65-8. PubMed ID: 26563809
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome.
    Hwang MH; Yoo JK; Luttrell M; Meade TH; English M; Christou DD
    Metab Syndr Relat Disord; 2015 Oct; 13(8):356-61. PubMed ID: 26302093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice.
    DeMarco VG; Habibi J; Jia G; Aroor AR; Ramirez-Perez FI; Martinez-Lemus LA; Bender SB; Garro M; Hayden MR; Sun Z; Meininger GA; Manrique C; Whaley-Connell A; Sowers JR
    Hypertension; 2015 Jul; 66(1):99-107. PubMed ID: 26015449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New antihypertensive drug class.
    Am J Nurs; 2003 Apr; 103(4):111. PubMed ID: 12677125
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacological sheet: eplerenone (Inspra), orally].
    J Pharm Belg; 2011 Sep; (3):93-4. PubMed ID: 21995102
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone's role in the management of complex cardiovascular disorders.
    Stewart Coats AJ; Shewan L
    Int J Cardiol; 2015 Dec; 200():1-2. PubMed ID: 26116081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of eplerenone on P-wave signal-averaged electrocardiogram in hypertensive patients with coronary artery disease.
    Kurisu S; Watanabe N; Ikenaga H; Shimonaga T; Higaki T; Iwasaki T; Mitsuba N; Ishibashi K; Dohi Y; Kihara Y
    Int J Cardiol; 2014; 172(1):e180-1. PubMed ID: 24439863
    [No Abstract]   [Full Text] [Related]  

  • 9. Eplerenone treatment of aortic stenosis. [letter].
    Marciniak TA
    Am Heart J; 2009 Mar; 157(3):e15; author reply e17. PubMed ID: 19249405
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of a beta-blocker and spironolactone on plasma homocysteine levels.
    Korkmaz ME; Atar I; Tayfun E; Yildirir A; Ulucam M; Ozin B; Muderrisoglu H; Turan M
    Int J Cardiol; 2003 Mar; 88(1):119-20. PubMed ID: 12659999
    [No Abstract]   [Full Text] [Related]  

  • 11. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of aldosterone receptor antagonists in the management of heart failure: an update.
    Nagarajan V; Chamsi-Pasha M; Tang WH
    Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone blockade in patients with systolic left ventricular dysfunction.
    Pitt B
    Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343
    [No Abstract]   [Full Text] [Related]  

  • 14. Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.
    Costa MB; Andrade Ezequiel DG; Morais Lovis JC; Oliveira MM; Baumgratz de Paula R
    J Clin Hypertens (Greenwich); 2010 Sep; 12(9):753-5. PubMed ID: 20883238
    [No Abstract]   [Full Text] [Related]  

  • 15. Evolving strategies for the use of spironolactone in cardiovascular disease.
    Jolobe OM
    Eur J Intern Med; 2013 Jun; 24(4):303-9. PubMed ID: 23245930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardioprotective effect of aldosterone antagonists for ventricular remodeling].
    Tatsumi T; Matsubara H
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():524-9. PubMed ID: 16897886
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker.
    Gamliel-Lazarovich A; Raz-Pasteur A; Coleman R; Keidar S
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1086-92. PubMed ID: 23524523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone. Pharmacia.
    Liew D; Martin J; Krum H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):316-22. PubMed ID: 12744223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.